Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …

We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524,
molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

The persistent COVID-19 pandemic since 2020 has brought an enormous public health
burden to the global society and is accompanied by various evolution of the virus genome …

In parallel with vaccination, oral antiviral agents are highly anticipated to act as
countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic …

The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the
rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS …

GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted
adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral …